Company Description
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy.
The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.
It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
| Country | United States |
| Founded | 2012 |
| IPO Date | Nov 8, 2019 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 227 |
| CEO | Antony Koblish |
Contact Details
Address: 1 Great Valley Parkway, Suite 24 Malvern, Pennsylvania 19355 United States | |
| Phone | 484 320 2930 |
| Website | telabio.com |
Stock Details
| Ticker Symbol | TELA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $13.00 |
| CIK Code | 0001561921 |
| CUSIP Number | 872381108 |
| ISIN Number | US8723811084 |
| Employer ID | 45-5320061 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Antony Koblish | Co-founder, President, Chief Executive Officer and Director |
| Roberto E. Cuca J.D. | Chief Financial Officer and Chief Operating Officer |
| Paul Talmo | Chief Technology Officer |
| Megan Smeykal | Vice President, Corporate Controller, Chief Accounting Officer and Principal Accounting Officer |
| D. Taylor Ocasio | General Counsel and Corporate Secretary |
| Jennifer Lou Armstrong | Senior Vice President of Human Resources |
| Gregory A. Firestone | Chief Commercial Officer |
| Michael Leonard | Senior Vice President of Technical Operations |
| Peter C. Murphy | Chief Commercial Officer |
| Louisa Smith | Investor Relations Contact Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SCHEDULE 13G | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 29, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 28, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 25, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 23, 2024 | 8-K | Current Report |
| Oct 23, 2024 | 424B5 | Filing |
| Oct 22, 2024 | 424B5 | Filing |